

Europe Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026

<https://marketpublishers.com/r/E48C4274F2C2EN.html>

Date: May 2020

Pages: 79

Price: US\$ 1,500.00 (Single User License)

ID: E48C4274F2C2EN

Abstracts

The Europe Osteoporosis Drugs Market would witness market growth of 4% CAGR during the forecast period (2020-2026).

Growth in the market for osteoporosis drugs is likely to be delayed due to side effects and risks involved with osteoporosis medications. For eg, heartburn, muscle and joint pain, diarrhea, and stomach or esophagus ulcers are risks associated with the drug class of bisphosphonates. Other than this, other classes of drugs also have side effects in patients. Many risks caused by osteoporosis medications include bone trauma, bone breaks, and urinary infection. Moreover, the patent expiry of new branded products and the restricted reimbursement by healthcare payers often adversely affect the growth of the market.

Rank ligand inhibitors may also be used in conjunction with other drugs to give a synergistic effect on the overall treatment regimen. It is also anticipated that this factor will be one of the key factors responsible for presenting lucrative opportunities. Other advantages related to ligand rank Inhibitors such as decreased bone cell turnover and increased bone mineral density, resulting in high demand.

The major factor contributing to the growth of the market for osteoporosis drugs is the

increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company

Scope of the Study

Market Segmentation:

By Route of Administration

Oral

Injectable and

Other Route of Administration

By Drug Class

Bisphosphonates

Rank Ligand Inhibitors

Parathyroid Hormone Therapy

Calcitonin

Selective Estrogen Inhibitors Modulator (SERM) and

Other Drug Classes

By Country

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

Companies Profiled

Amgen, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline PLC (GSK)

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceuticals Industries Ltd.

Allergan PLC

Eli Lilly and Company

Unique Offerings from KBV Research

Exhaustive coverage

Highest number of market tables and figures

Subscription based model available

Guaranteed best price

Assured post sales research support with 10% customization free

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 Europe Osteoporosis Drugs Market, by Route of Administration
 - 1.4.2 Europe Osteoporosis Drugs Market, by Drug Class
 - 1.4.3 Europe Osteoporosis Drugs Market, by Country
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
 - 2.1.1 Overview
 - 2.1.2 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION

- 3.1 Europe Oral Market by Country
- 3.2 Europe Injectable Market by Country
- 3.3 Europe Other Route of Administration Market by Country

CHAPTER 4. EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS

- 4.1 Europe Bisphosphonates Market by Country
- 4.2 Europe Rank Ligand Inhibitors Market by Country
- 4.3 Europe Parathyroid Hormone Therapy Market by Country
- 4.4 Europe Calcitonin Market by Country
- 4.5 Europe Other Drug Class Market by Country

CHAPTER 5. EUROPE OSTEOPOROSIS DRUGS MARKET BY COUNTRY

- 5.1 Germany Osteoporosis Drugs Market
 - 5.1.1 Germany Osteoporosis Drugs Market by Route of Administration
 - 5.1.2 Germany Osteoporosis Drugs Market by Drug Class
- 5.2 UK Osteoporosis Drugs Market
 - 5.2.1 UK Osteoporosis Drugs Market by Route of Administration
 - 5.2.2 UK Osteoporosis Drugs Market by Drug Class
- 5.3 France Osteoporosis Drugs Market
 - 5.3.1 France Osteoporosis Drugs Market by Route of Administration
 - 5.3.2 France Osteoporosis Drugs Market by Drug Class
- 5.4 Russia Osteoporosis Drugs Market
 - 5.4.1 Russia Osteoporosis Drugs Market by Route of Administration
 - 5.4.2 Russia Osteoporosis Drugs Market by Drug Class
- 5.5 Spain Osteoporosis Drugs Market
 - 5.5.1 Spain Osteoporosis Drugs Market by Route of Administration
 - 5.5.2 Spain Osteoporosis Drugs Market by Drug Class
- 5.6 Italy Osteoporosis Drugs Market
 - 5.6.1 Italy Osteoporosis Drugs Market by Route of Administration
 - 5.6.2 Italy Osteoporosis Drugs Market by Drug Class
- 5.7 Rest of Europe Osteoporosis Drugs Market
 - 5.7.1 Rest of Europe Osteoporosis Drugs Market by Route of Administration
 - 5.7.2 Rest of Europe Osteoporosis Drugs Market by Drug Class

CHAPTER 6. COMPANY PROFILES

- 6.1 Amgen, Inc.
 - 6.1.1 Company Overview
 - 6.1.2 Financial Analysis
 - 6.1.3 Research & Development Expense
 - 6.1.4 Recent strategies and developments:
 - 6.1.4.1 Partnerships, Collaborations, and Agreements:
 - 6.1.4.2 Approvals:
- 6.2 F. Hoffmann-La Roche Ltd.
 - 6.2.1 Company Overview
 - 6.2.2 Financial Analysis
 - 6.2.3 Segmental and Regional Analysis
 - 6.2.4 Research & Development Expense
- 6.3 GlaxoSmithKline PLC (GSK)
 - 6.3.1 Company Overview
 - 6.3.2 Financial Analysis

- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.4 Merck & Co., Inc.
 - 6.4.1 Company Overview
 - 6.4.2 Financial Analysis
 - 6.4.3 Segmental and Regional Analysis
 - 6.4.4 Research & Development Expenses
- 6.5 Novartis AG
 - 6.5.1 Company Overview
 - 6.5.2 Financial Analysis
 - 6.5.3 Segmental and Regional Analysis
 - 6.5.4 Recent strategies and developments:
 - 6.5.4.1 Partnerships, Collaborations, and Agreements:
- 6.6 Pfizer, Inc.
 - 6.6.1 Company Overview
 - 6.6.2 Financial Analysis
 - 6.6.3 Segmental and Regional Analysis
 - 6.6.4 Research & Development Expense
- 6.7 Sun Pharmaceutical Industries Ltd.
 - 6.7.1 Company Overview
 - 6.7.2 Financial Analysis
 - 6.7.3 Regional Analysis
 - 6.7.4 Research & Development Expense
- 6.8 Teva Pharmaceutical Industries Ltd.
 - 6.8.1 Company Overview
 - 6.8.2 Financial Analysis
 - 6.8.3 Regional Analysis
 - 6.8.4 Research & Development Expenses
- 6.9 Allergan PLC
 - 6.9.1 Company Overview
 - 6.9.2 Financial Analysis
 - 6.9.3 Segmental and Regional Analysis
 - 6.9.4 Research & Development Expense
- 6.1 Eli Lilly and Company
 - 6.10.1 Company Overview
 - 6.10.2 Financial Analysis
 - 6.10.3 Regional Analysis
 - 6.10.4 Research & Development Expense

List Of Tables

LIST OF TABLES

TABLE 1 EUROPE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 2 EUROPE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 3 EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 4 EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 5 EUROPE ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 6 EUROPE ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 7 EUROPE INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 8 EUROPE INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 9 EUROPE OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 10 EUROPE OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 11 EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 12 EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 13 EUROPE BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 14 EUROPE BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 15 EUROPE RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 16 EUROPE RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 17 EUROPE PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 18 EUROPE PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 19 EUROPE CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 20 EUROPE CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 21 EUROPE OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019,

USD MILLION

TABLE 22 EUROPE OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026,
USD MILLION

TABLE 23 EUROPE OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019,
USD MILLION

TABLE 24 EUROPE OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026,
USD MILLION

TABLE 25 GERMANY OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD
MILLION

TABLE 26 GERMANY OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD
MILLION

TABLE 27 GERMANY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 28 GERMANY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 29 GERMANY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 -
2019, USD MILLION

TABLE 30 GERMANY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 -
2026, USD MILLION

TABLE 31 UK OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 32 UK OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 33 UK OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 34 UK OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 35 UK OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019,
USD MILLION

TABLE 36 UK OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026,
USD MILLION

TABLE 37 FRANCE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 38 FRANCE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 39 FRANCE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 40 FRANCE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF
ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 41 FRANCE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 -
2019, USD MILLION

TABLE 42 FRANCE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 -
2026, USD MILLION

TABLE 43 RUSSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 44 RUSSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 45 RUSSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 46 RUSSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 47 RUSSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 48 RUSSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 49 SPAIN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 50 SPAIN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 51 SPAIN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 52 SPAIN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 53 SPAIN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 54 SPAIN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 55 ITALY OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 56 ITALY OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 57 ITALY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 58 ITALY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 59 ITALY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 60 ITALY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 61 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 62 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 63 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 64 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 65 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG

CLASS, 2016 - 2019, USD MILLION

TABLE 66 REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG

CLASS, 2020 - 2026, USD MILLION

TABLE 67 KEY INFORMATION – AMGEN, INC.

TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.

TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)

TABLE 70 KEY INFORMATION - MERCK & CO., INC.

TABLE 71 KEY INFORMATION – NOVARTIS AG

TABLE 72 KEY INFORMATION – PFIZER, INC.

TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.

TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.

TABLE 75 KEY INFORMATION – ALLERGAN PLC

TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY

List Of Figures

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH

I would like to order

Product name: Europe Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026

Product link: <https://marketpublishers.com/r/E48C4274F2C2EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E48C4274F2C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970